Before we discuss what is MG Therapeutics, let us have a quick look at what is MG (Myasthenia Gravis)
This is a disorder in the neuromuscular regions which causes weakness in the muscles by the junction of neuromuscular the receptors by it decreasing the acetylcholine numbers.
Though the symptom of this disease can be observed in the early ages of all patients, it is only prominent in adulthood.
This is seen on the patient by showing weakness in the eyelids with droopiness than can and may result in blurred vision.
This can and will cause a major breakdown in the adult’s normal life, as it will cause double vision and causing the patient to suffer from excessive or major fatigue when doing normal physical work.
Fortunately, MG can be detected by a physical examination and by diagnostic radiological tests like Computer-Aided Tomography scans (CT’s) and or Magnetic Resonance Imaging scans (MRIs)
MG Therapeutics is only approved by one United States company for treatment by the US Food and Drug Administration (USFDA).
Some insights into the MG Segments in the Pipeline
Most of the patients or candidates treating in this pipeline study has the developed drug administered intravenously as this is the way any type of drug can reach the whole system instantly. In this way, it increases the drug’s bioavailability and has been the only administration process that shows promising clinical study results
This positive result has been a stepping stone for further studies to be administered in the MG Pipeline Therapeutics.
With this positive feedback and study results, more companies are now stepping forward with their clinical trials and are also showing positive signs and results in different phases for MG drug development.
One such company announced in December 2018 positive results in one of the drug studies and announced the drug as well.
The study results concluded that this new drug is not only safe to use but has a high tolerability profile and was consistent with both their first and second phases.
With little or no adverse effects (AE) to this new drug reported in the majority of the patients and only mild AE in some but was found by researchers to be unrelated to the drug treatment of this new drug, showing promising signs of a successful trial.
